Infections in myelodysplastic syndromes.
Myelodysplastic syndromes are associated with a risk of severe infections. While neutropenia is likely to be the main predisposing factor, several other immune defects have been reported, including impaired neutrophil function, B-, T- and NK-cell defects and the possible consequences of iron overload due to red blood cell transfusions. The advanced age of most patients, their frequent comorbidities, and the fact that drugs such as hypomethylating agents and lenalidomide, which are effective in myelodysplastic syndromes but can transiently worsen neutropenia, may increase the risk of infection and their severity in this context. The majority of infections in myelodysplastic syndromes are bacterial, while the incidence of fungal infections is not well known and viral infections seem to be rare. No prophylactic measures against infections have demonstrated efficacy in myelodysplastic syndromes. However, pending more data, we propose here some recommendations for the management of patients with myelodysplastic syndromes. In the future, an important contribution can be made by prospective trials testing the efficacy of prophylactic and therapeutic approaches to infection in these patients, especially in the context of the new drugs available for myelodysplastic syndromes.
Department of Hematology Henri Mondor University Hospital, 94000 Créteil, France. andrea.toma@hmn.aphp.fr
Andréa
A
Toma
Pierre
P
Fenaux
François
F
Dreyfus
Catherine
C
Cordonnier
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003141:Communicable Diseases / Q000209:etiology* / Q000628:therapy; D006801:Humans; D019190:Iron Overload / Q000150:complications; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D009503:Neutropenia / Q000209:etiology
D000970:Antineoplastic Agents